The life science company supplies large pharmaceutical and biotech companies with customized antibodies for research purposes. For SHS, it is the first investment from its SHS V fund, which had its first closing in July 2018.
We have sold our shareholding in Tuttlingen-based Emerging Implant Technologies GmbH (EIT) to Johnson & Johnson Medical GmbH. In 2016 we have invested in the medtech company as lead investor.
The fifth generation of SHS funds is also focused on the life sciences and medical technology sector, and thus on the growing global healthcare market with innovative and strong Players.
With the acquisition of Innocath, Novo Klinik-Service is complementing its product portfolio in the field of airway management. The partnership will open up further growth opportunities and sales activities.
SHS partner Dr. André Zimmermann talks to the FAZ about SHS’ new medical technology fund
Miracor Medical Systems has raised the capital as part of a Series D financing round. Next to other existing investors SHS also participated in the financing round.
The European Investment Bank (EIB) will provide financing of EUR 25m to AMW GmbH in Warngau, Germany. The financing will enable AMW to increase R&D activities, conduct clinical trials and expand production capacity.
CoreMedic is a start-up developing innovative, transfemoral repair systems to treat heart valve malfunctions. SHS is investing from its fourth fund generation to finance CoreMedic’s further growth and the clinical application of its innovative products.
